TEST PAPER - XARIA TABLETS

Marks
Time

50
30

mins
---------------------------------------------------------------------------------Q.1 Fill in the blanks ( Each blank 1 mark)
1. ____________________ is clinically defined as a symptomatic disorder of the nose induced by
an IgE-mediated inflammation after allergen exposure of the membranes lining the
nose.
2. An extremely common disease worldwide, affecting _________ % of the population
___ in ___ people are said to be suffering from rhinitis.
3 How are the symptoms caused

Irritation of free nerve endings

Increased mucus production
Vasodilation
Increased vascular permeability

_______________________
_______________________
_______________________
_______________________

4. Laboratory Tests for Allergic Rhinitis

- _________________ Test
- Peak ________________ Flow Rate
- Rhinomanometry (Study and measurement of _____________ and _____________ with
Rhinomanometer )
5. Medications used to treat allergic rhinitis:

______________________________
______________________________
______________________________
______________________________
______________________________
______________________________
______________________________

6. ARIA Guidelines means : ___________________________________________________

7. Uncontrolled Allergic rhinitis may lead to worsening of coexisting _________________ .
8. Classification of Allergic Rhinitis
______________________________
______________________________
______________________________
______________________________
9. The prevalence of rhinitis among asthmatic patients is high, ranging from ________ %,while,
___________ % of patients with allergic rhinitis also have asthma.
10. Proposed Mechanisms for Pathologic Link Between AR co-existing with Asthma.
___________________________________________________________
___________________________________________________________
___________________________________________________________
___________________________________________________________
11.

________is a selective and orally active leukotriene receptor antagonist that

inhibits the cysteinyl leukotriene (CysLT1) receptor.

12.

________
histamine H1 receptors

is a potent and highly selective antagonist of the peripheral

Q.2 Match the following :

1.

Levocetrizine

a.

2.
3.
4.

Intermittent AR
Blocked Leukotrienes
Persistent AR

b.
c.
d.

For relief and/or prevention of symptoms of Allergic

Rhinitis in adults > 15 yrs of age
3-11 hrs. after exposure
Reduces sneezing, nasal itching and discharge
5-30 mins. after exposure

5.

e.

Takes care of the Late Allergic Reaction

6.

Eosinophil Cationic
Protein
Montelukast

f.

< 4 days per week/or < 4 weeks

7.

Blocked Histamine

g.

8.
9.
10.

Xaria OD
Early Phase Response
Late Phase Response

h.
i.
j.

Reduces nasal congestion with potent anti-inflammatory

effect
4 days per week/and 4 weeks
Takes care of the Early Allergic Reaction
Inflammatory Marker in Perennial Allergic Rhinitis

Answers : (1-

),(2-

),(3-

),(4-

),(5-

),(6-

),(7-

),(8-

),(9-

),(10-

).

Q.3 State whether the statement is True or False.

1. Although the symptoms of AR may be described as benign, the condition is included in the top
10 causes of chronic disability. (
).
2. Rhinitis with partial or complete airway obstruction may contribute significantly to asthma
Symptoms (
).
3. Treating allergic rhinitis helps in controlling asthma symptoms, improving Broncho Hyper
Responsiveness (BHR) and improving lung function tests (
).
4. Leukotrienes are a family of inflammatory lipid mediators synthesized from arachidonic acid
by a variety of cells, including mast cells, eosinophils, neutrophils, basophils, and
macrophages (
).
5. Levocetrizine is alkaline stable while Montelukast is acid stable, hence requires Bilayer
tablets and Alu-Alu pack for stability (
).
6. Combining montelukast with levocetirizine significantly improved QOL and gave additional

benefits compared to individual agents for patients whose QOL is impaired by Perennial
Allergic Rhinitis (
).

7. Both INCS as monotherapy and oral antihistamine plus montelukast as co-therapy were
equally effective in the treatment of Seasonal AR (
).
8. Treatment with XARIA can help increase the dose of inhaled and intranasal steroids
(
).
******************************************